Please assess the completion status of the following clinical trial:

Trial Title: Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Patients diagnosed with symptomatic infection by Plasmodium falciparum microscopically confirmed in blood smear at Day-1 visit~* Fever (tympanic or rectal temperature ≥ 38 C) or documented history of fever within the last 24h~* Asexual parasitemia of ≥ 2 000 parasites/μL in blood smear at D-1 visit~* Signed Informed Consent Form by the parents or legal guardian~* Age: 12 to 17 years old for step 1~* Age: 2 to 11 years old for step 2 and step 3~Exclusion criteria:~* Participation in another clinical trial within the last 3 months or participation within a different cohort in this PDY11737 clinical trial or participation to previous trial with SAR97276~* Documented history of adequate treatment with antimalarials expected to be effective within the preceding 72 hours~* Severe concomitant disease (including concomitant febrile illnesses or infection)~* Any sign suggestive of severe malaria~* Severe malnutrition~* Asexual parasitemia: Plasmodium falciparum \> 100,000 parasites/μL in blood smear at D-1 visit~* Previous treatment within 3 weeks prior to inclusion, and concomitant treatment with potent CYP3A4 inhibitors or CYP3A4 inducers or CYP2D6 substrates or potent CYP2D6 inhibitors~* Known serious adverse event reaction or hypersensitivity to Artemisinin-Based Combination Therapy (ACTs) or any contraindications from the positive control therapy (Artemisinin Combined Treatments) or warning/precaution of use as defined in the respective National Product Labeling~* Pregnant or breast-feeding women~* Women of childbearing potential not protected by effective contraceptive method of birth control, or not willing to use an effective contraceptive(s) method(s) for the duration of the study (e.g.: double barrier method), and/or who are unwilling or unable to be tested for pregnancy,~* CPK above 3 ULN,~* Underlying hepatobiliary disease or ALT\>3 ULN.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Step 1 (SAR97276A od) (Type: EXPERIMENTAL): 1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
- Step 1 (SAR97276A bid) (Type: EXPERIMENTAL): 1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
- Step 1 (ACTs) (Type: ACTIVE_COMPARATOR): 1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
- Step 2 (SAR97276A) (Type: EXPERIMENTAL): 1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
- Step 2 (ACTs) (Type: ACTIVE_COMPARATOR): 1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
- Step 3 (SAR97276A) (Type: EXPERIMENTAL): 1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval